“I continue to be encouraged by the progress across our CAB platform, particularly with our Phase 1 dose-escalation study evaluating our dual conditionally-binding EpCAM and CD3 bispecific T-cell engager,” said Jay Short, chairman, CEO and co-founder of BioAtla (BCAB), Inc. “It is also gratifying to observe the maturing Phase 2 datasets, demonstrating exceptional overall survival among patients treated with Mec-V and potent anti-tumor activity observed in refractory HPV+ head and neck cancer patients treated with Oz-V.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAB:
- BioAtla announces poster presentations at 2025 AACR meeting
- BioAtla price target lowered to $1 from $5 at Citizens JMP
- BioAtla’s Earnings Call: Clinical Progress and Strategic Outlook
- Positive Outlook for BioAtla: Strategic Moves and Promising Developments Signal Potential Upside
- BioAtla price target lowered to $10 from $13 at BTIG